What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2026-03-12 compared with 2025-03-20 · 10 added, 36 removed, 9 unchanged (84% of the section changed)

8 unchanged sentences

funds for the development of our plan of operation.

On March 18, 2025, our board

of directors approved to increase the amount of shares of Common Stock available under the 2021 Plan from 4,800,000 to 9,000,000.

On March 18, 2025, our board

of directors approved the following grants pursuant to our 2021 Plan:

(i) 1,000,000 options to purchase

shares of Common Stock to Mr.

Yossef Balucka, CEO, at an exercise price of $0.21 per share, and vest in three equal installment of 33%

at the end of each year.

The options expire after six (6) years from the date of grant, and such other terms and conditions set forth

in our 2021 Plan.

(ii) 500,000 options to our

Common Stock to Mr.

Vadim Maor, CTO, at an exercise price of $0.21 per share.

The options have the following vesting schedule:

the options will vest after 12 months and the remaining portion will vest in eight equal installments over eight quarters.

expire after six (6) years from the date of grant, and such other terms and conditions set forth in our 2021 Plan.

(iii) 120,000 options to purchase

shares of Common Stock to Ms.

Keren Gousman Golan, director.

The options were granted at an exercise price of $0.21 per share and vest

in three equal installment of 33% at the end of each year.

The options expire after six (6) years from the date of grant, and such other

terms and conditions set forth in our 2021 Plan.

(iv) 400,000 options to purchase

shares of Common Stock to Mrs.

Alexandra Papaconstantinou, Managing Director of Duke Greece.

The options were granted at an exercise price

of $0.21 per share and vest in three equal installments of 33% at the end of each year.

The options expire after six (6) years from the

date of grant, and such other terms and conditions set forth in our 2021 Plan.

(v) 50,000 options to purchase

shares of Common Stock to Mr.

Shlomo Zakai, CFO, at an exercise price of $0.21 per share, and vest in three equal installment of 33% at

the end of each year.

The options expire after six (6) years from the date of grant, and such other terms and conditions set forth in

our 2021 Plan.

On March 10, 2026, our board of directors approved the following grants pursuant

to our 2021 Plan:

(i) options to purchase 16,000 shares of our common stock to each of Yossef Balucka, our Chief Executive Officer, and

Erez Nachtomy, our Vice Chairman;

(ii) options to purchase 10,000 shares of our common stock to Shlomi Zakai, our Chief Financial Officer;

and (iii) options to purchase 4,000 shares of our common stock to each of Vadim Maor, our Chief Technology Officer, Eran Antebi, a member

of our board of directors, and Keren Gousman, a member of our board of directors.

Each of the aformentioned options have an exercise price

of $7.88 per share, a term of six (6) years from issuance and vest over a three (3) year period, with one third vesting on each of the

first three anniversaries of the dates of grant.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity